FDA 发布细胞与基因治疗产品效价保证指南,替代 2011 年效价检测指南
Potency of Cell and Gene Therapies - Draft FDA Guideline
FDA 生物制品评价与研究中心(CBER)发布细胞与基因治疗产品效价保证指南,替代 2011 年 1 月的效价检测指南。指南适用于按 PHS 法案第 351 条作为生物制品监管的 CGT 产品,覆盖从 IND 到 BLA 及获批后生命周期,并声明不具法律约束力,排除项包括传染病疫苗、噬菌体产品、活体生物治疗产品、粪菌移植产品和变应原产品。
The U.S. Food and Drug Administration (FDA), through its Center for Biologics Evaluation and Research (CBER), has issued final guidance on assuring the potency of cellular and gene therapy (CGT) products. It supersedes the January 2011 guidance, “Potency Tests for Cellular and Gene Therapy Products.” Potency is the specific ability of a product to achieve its intended effect. Developing potency tests is considered challenging because CGT products are highly diverse and tests need to be designed for the specific product. Objective The guidance describes a science- and risk-based approach. Its objective is to ensure that every released lot has the ability to achieve the intended therapeutic effect. Potency testing is only one component of an overall strategy, which also includes process design, process control, material control and in-process controls. Scope The guidance applies to CGT products regulated as biological products under Section 351 of the Public Health Service Act (PHS Act), throughout the product lifecycle—from IND development through the BLA and the lifecycle of the licensed product. Exclusions include, among others, vaccines for infectious disease indications, bacteriophage products, live biotherapeutic products, fecal microbiota transplantation products and allergenic products. The guidance is not legally binding; it describes the FDA’s current thinking. Key Points Regulatory framework: Each lot of a licensed product must be tested for potency. Changes must be assessed in advance for their impact on potency. During clinical investigations, the FDA may impose a clinical hold if potency is not adequately assured and this could expose participants to an unreasonable and significant risk, or if required potency information is missing. For studies intended to provide substantial evidence of effectiveness, inadequate potency assurance may also be considered a clear design deficiency. CGMP considerations: The manufacturing process, starting materials, containers, process controls and release tests must help assure potency. Developing a potency strategy: The foundation is quality risk management in accordance with ICH Q9(R1). This includes the Quality Target Product Profile (QTPP), critical quality attributes (CQAs), critical process parameters (CPPs), risk assessment and a control strategy. Phased implementation: The strategy is refined as the program progresses. Before clinical studies involving significant risk—and before studies intended to provide substantial evidence of effectiveness for a marketing application—the control strategy should include at least one suitable release assay, either physicochemical or biological, that quantifies a potency-related CQA. Phase-appropriate acceptance criteria should ensure that subpotent lots are rejected. Assays should be qualified for their intended purpose. Evidence should also be available that potency-related CQAs remain stable during storage and preparation for administration. Manufacturers should engage with CBER early. This is a nonbinding recommendation, not a separate statutory requirement. Potency assays: Assays are used for lot release, stability assessment, in-use and delivery-device compatibility, and comparability after manufacturing changes. For most CGT products, lot release testing should include at least one phase-appropriate bioassay. Multiple release assays are typically recommended for potency-related CQAs that are not otherwise adequately controlled; in particular, a bioassay should be used when it can effectively measure a relevant biological activity. Assay requirements: Precision, accuracy, specificity and robustness; avoidance of unnecessary redundancy; and minimization of animal use. Product-specific approaches: The guidance discusses cellular products, products with a short shelf life, viral vectors, patient-specific gene therapies and tissue-engineered products. Assay lifecycle: The guidance addresses system and sample suitability criteria, reference materials and their qualification, validation of release assays, and assay transfers and changes. Acceptance criteria: These should be quantitative and include a lower limit, with an upper limit where appropriate. “Report only” acceptance criteria are not recommended for release testing. Relevance to YouThe guidance is relevant to QA, development and regulatory teams involved in CGT manufacturing, particularly in relation to risk management, assay validation and release strategies. It is not directly applicable to EU marketing authorizations; nevertheless, it may be useful as a technical reference, especially for companies operating internationally. The guidance itself is limited to certain CGT products regulated under Section 351 of the PHS Act. For further details, see the FDA guidance P.S. Current developments in bioassays and potency assays, both regulatory and scientific, will be covered in the corresponding conference track at PharmaLab 2026 on November 24/25 in Darmstadt.
来源:ECA GMP News · gmp-compliance.org